Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems—including clinical metabolomic data sets—to apply to genetically-validated targets in metabolic diseases and cancer.

Leadership

Marion Dorsch, PhD
Marion Dorsch, PhD
President & CSO
Jeff Goater
Jeff Goater
Interim CEO

Founders

Jared Rutter, PhD
Jared Rutter, PhD
Professor of Biochemistry
University of Utah
HHMI Investigator
Ralph J DeBerardinis, MD, PhD
Ralph J DeBerardinis, MD, PhD
Professor, Children’s Research Institute
University of Texas Southwestern Medical Center
HHMI Investigator

Board of Directors

John Josey, PhD
Chairman
The Column Group


Adam Goulburn, PhD
Lux Capital


Helen Hobbs, MD
University of Texas Southwestern Medical Center
HHMI Investigator
Jeff Goater
Interim CEO
The Column Group


Marion Dorsch, PhD
President and CSO


Thilo Schroeder, PhD
Nextech
News
August 24, 2021
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
Careers
Join our team as we expand into our new Cambridge-based location.

Investors

TCG
LUX
Nextech